Archive | Next Phase Archive RSS feed for this section

All-Star Lineup: See These Industry Experts Speak at RESI San Francisco

12 Dec

By Claire Jeong, Director of Research, Asia BD, LSN


LSN is busily preparing for our largest conference of the year, RESI San Francisco, during JPM week on Tuesday, January 14th, 2020. In our last RESI SF conference, we had over 1,200 attendees join, making it our largest conference to date.

This time, we are featuring 3 tracks of panels and workshops that encompass a wide variety of sectors within life science and healthcare, including more specialized topics relevant to current industry trends. For the very first time, we are also dedicating an entire track for Featured Company Pitch Sessions, which will be a valuable opportunity for companies to showcase their technologies.

The ultimate goal of our panels and workshops is to provide valuable insights to fundraising early-stage companies, especially on how groups can effectively seek to work with investors and strategic partners. RESI strives to feature industry players from large VCs to new funds, from large corporations to angel investors, to lend their expertise to the entrepreneurs attending RESI. With excellent returning speakers and many new contributors, the panel lineup at this RESI is sure to be one of the best we’ve had.

For those who are already registered for RESI, we highly encourage you to attend some panels that are relevant to your company’s interests. If you’re interested in hearing from and meeting active industry experts, but haven’t registered, it’s not too late!

Without further ado, here are some of the panelists who will be joining our panels and workshops at RESI San Francisco:


Chris Haskell
VP, Head Open Innovation Center – North America West

Joyce Chan
Director of External R&D

Anne Wellington
Managing Director
Cedars-Sinai Health Accelerator

Richard Proscia
Senior Associate
Providence Ventures

Brent Stackhouse
Managing Director
Mount Sinai Ventures

Wei Wu
Senior Associate
Illumina Ventures

Mike Ryan
Co-Founder & CEO
Bullet Point Network

Brent Ahrens
General Partner
Canaan Partners

Christina Takke
Co-Founder & Managing Partner
V-Bio Ventures

Roel Bulthuis
Managing Director
INKEF Capital

Claudia Karnbach
Head of Business Development & Licensing, Oncology

David Cruikshank
ARCH Venture Partners

Dani Bach
+ND Capital

Bill Hyun
Venture Partner
Genoa Ventures

Chihiro Hosoya
BD/VC Head
Astellas Rx+ Business Accelerator

Ronald Dorenbos
Head, Innovation Management & Scouting

Nicholas Mourlas
Senior Director, New Ventures
Johnson & Johnson

Gerry Brunk
Managing Director
Lumira Ventures

Neil Swami
Catalyst Health Ventures

Z Haroon
Chairman and General Partner
Julz Co LLC

Lauren Tyra
Principal Scientist
Green Park & Golf Ventures

Kwame Ulmer
Venture Partner
Wavemaker Three-Sixty Health

Diana Saraceni
Founder and Managing Partner
Panakes Partners

Ted Driscoll
Managing Partner
DigitalDx Ventures

Noel Jee
Senior Associate
Illumina Ventures

Sharon Chan
Head of JLABS @Shanghai
Johnson & Johnson

Weiyong Sun
Senior Director, Specialty Medicine Search & Evaluation, Global Business Development
Daiichi Sankyo

Lu Han
Director of Business Development, Asia Pacific
Lumira Ventures

Yao Li Ho
Senior Director of Business Development
LYFE Capital

Yanghuan Bao
Investment Partner
BOHE Angel Fund

Michelle Gon
McDermott Will & Emery Shanghai Offices

David Xu
Chief Business Officer
Viva Biotech

Frank Yan
Operating Partner
3E Bioventures

Elona Baum
Managing Director
DEFTA Partners

Tad Weems
Managing Director, Early Stage Partnerships
Agilent Technologies

Jiwon Huh
Director of Corporate Strategy
Boryung Holdings

Lu Zhang
Founder & Managing Partner
Fusion Fund

Xinhong Lim
Vickers Venture Partners

Yizhen Dong
11.2 Capital

Miraj Sanghvi
DigiTx Partners

RESI Partnering Tips: How to Fill Your Day with Meetings on January 14th

12 Dec

By Bryanna Allison, Business Development Manager, LSN

If you’ve registered for RESI San Francisco, then it’s likely that your goal is to book a strong slate of meetings, followed by a full day of face-to-face meetings with investors at RESI.  Here is our advice for partnering success at RESI:

  • Fill out your profile! This will provide investors with information above and beyond what you can fit in your intro message. If you fill out the key fields in your profile, attendees can revert back there for more information.
  • Use the filters in the sidebar when searching for meeting partners! Whether you are a startup, investor or service provider, the filters are in place to make your lives easier. You can pick a category of attendees to search, then use the filters to narrow down to the most relevant fits for you, such as investors who are interested in your sector.
  • Send as many relevant meeting requests as possible. Always use the “book a meeting” option for initial contact.
  • Put effort into the message you are sending along with your meeting requests. Tell them what you’re doing, who you are, why you’d be a great fit to work together and what you’re looking to get out of the relationship. Keep it concise, but informative!
  • Follow up on your requests. You can use the “send a message” option in RESI Partnering to send follow-up notes, or if you have the investor’s contact info you could send an email directly.
  • Continue to check the platform regularly. New investors, startup and service provider attendees are added every day. If you want to focus on newly added profiles, you can change the order of search results from ‘Order alphabetically’ to ‘Order by date approved’ and look at who’s joined since your last visit.
  • Join our partnering tutorials so you can see it all firsthand! Please visit our website for the complete partnering tutorial schedule.
  • Bring your partnering schedule to RESI – either print it out or have it available on your phone.

Using the partnering platform effectively can help you make the most out of RESI! It’s there so you know exactly who is coming and exactly who you need to talk to. Don’t miss out on our largest event of the year and this excellent opportunity to network with over 500 life science investors.

Attend the Enmore Bio Conference to Connect with China’s Bio Industry – Suzhou, China February 20-22, 2020

12 Dec

By Candice He, Global Investment Strategist, LSN

As a co-organizer of RESI Shanghai, Enmore has become a valuable partner of Life Science Nation, utilizing their expertise in the local market and as conference organizers to make RESI a success, with more than 450 investors, startups and service providers in attendance. LSN and Enmore have a common goal of creating an international ecosystem for advancing life science technologies to market in a global economy, and will continue to partner to achieve this. For those interested in exploring the China market and establishing relationships with key players in the China life science ecosystem, we invite you to attend the Enmore Bio Conference, taking place at the Suzhou International Expo Center from February 20-22, 2020.

What is EBC?

Enmore Bio Conference (EBC) is the largest and most influential bio-industry conference in China, as well as the most open conference platform jointly created by Enmore Healthcare, the organizer, and many industry associations, institutions, companies and experts for the whole industry chain.

EBC consists of four parallel conferences: the 10th Antibody Drugs & Novel Biological Summit, the 8th Molecular Diagnostics Summit, the 6th Immunotherapy Industry Summit, and the 3rd 17TALK Healthcare Investment & Financing Leadership Forum. The four-in-one event covers topics concerning the whole industry chain of diagnosis, treatment and medication, and other topics like CDx, target development, clinical research and policy discussion will also be touched through a dozen of special forums. The Enmore Bio Exhibition, as part of this event, will attract more than 200 suppliers of instruments, consumables and services. The EBC, which combines conference and exhibition, has become a benchmark platform for high-level exchanges and cooperation in the bio-industry in China and abroad.

Conference website:

Why choose EBC?

EBC is committed to building China’s largest and most influential bio industry event through four parallel conferences, a dozen of co-organized forums, three invited-only meetings for CEOs and pre-event business visits. More than 150 enterprise leaders and experts will make presentations during this event.

Previous reports of EBC:

Co-organizations of EBC 2020

Guangzhou KingMed Diagnostics Group Co., Ltd.


Wuhan Tongji Hospital

Renmin Hospital Of Wuhan University

Shanghai Junshi Biosciences Co., Ltd.

Hengrui Medcine

Innoforce Pharmaceuticals Co., Ltd.

TOT Biopharm


Everbright Medical & Healthcare Fund

EBC parallel conferences:

10th Antibody Drugs & Novel Biological Summit

The 10th Antibody Drugs & Novel Biological Summit is co-organized by Junshi Biosciences, Hengrui Medicine, Innoforce Pharmaceuticals, TOT BIOPHARM and SAPA-China. It covers the whole process of early research and development, process development, mass production, industrialization and commercialization. We will bring together CEOs and top leaders of functional departments of local listed companies, as well as heads of R&D, production, quality, process and business of antibody enterprises at home and abroad through a platform of exchanges and cooperation for thousands of people.

8th Molecular Diagnostics Summit

The 8th Molecular Diagnostics Summit is co-organized by Enmore and KingMed Diagnostics. This time we focus on “molecular diagnostics market structure and corporate strategy”, “multi-platform detection technology for clinical diagnosis” and “to create competitive molecular diagnostic products”. Authoritative experts in precision medicine and outstanding enterprises such as Jiangsu Center for Clinical Laboratories, Shanghai Center for Clinical Laboratory, Berry Genomics, Geneseeq, and KingMed Diagnostics Group will participate in this summit. An invited-only CEO meeting will happen during the summit, organized by Clinical Laboratories leaders.

6th Immunotherapy Industry Summit

The 6th Immunotherapy Industry Summit aims to provide businesses with the industrialization of cellular immunotherapy in the next two years. The forum is jointly developed by experts and scholars in the field of cellular immunotherapy study, quality control leaders of first-tier companies, and CEOs of domestic and foreign companies with extensive industrialization experience! Companies and institutions involved include Fosun Kite Biotechnology Co., Ltd, JW Therapeutics, Cellular Biomedicine Group, PersonGene, Tongji Hospital, etc.

3rd 17TALK Healthcare Investment & Financing Leadership Forum

The 3rd 17TALK Healthcare Investment & Financing Leadership Forum is co-hosted by Enmore Healthcare and Everbright Medical & Healthcare Fund. The forum features healthcare investment trends and corporate listing, inviting local and international top investors to participate in the discussions. Special financing roadshows will be held to provide a financing platform for enterprises.

Who will attend EBC?

EBC 2019 attracted 2,208 attendees, and EBC 2020 is expected to exceed 3,000 attendees. The participating groups include entrepreneurs, scientists, clinicians, investors and suppliers, mostly CEOs and heads of R&D, production, quality, process and commercialization.

Part of EBC 2019 attendees

Antibody Drugs BIO-THERA Immunotherapy Gracell
Antibody Drugs BeiGene Immunotherapy Lion TCR
Antibody Drugs JOINN Laboratories (Beijing) Immunotherapy HRYZ BIO TECH CO.
Antibody Drugs Boehringer-Ingelheim Immunotherapy GENE
Antibody Drugs KANGHONG PHARMACEUTICAL Immunotherapy CARsgen Therapeutics
Antibody Drugs TOT BIOPHARM Immunotherapy Nanjing Legend Pharmaceutical & Chemical Co., Ltd
Antibody Drugs HARBOUR Immunotherapy Genscript
Antibody Drugs Hutchison MediPharma Immunotherapy IASO BIO
Antibody Drugs NCPC Immunotherapy Innovative Cellular Therapeutics Co.,Ltd.
Antibody Drugs CR PHARMA COMM Immunotherapy Shanghai Cell Therapy Group Co.LTD
Antibody Drugs Pfizer Immunotherapy JW Therapeutics
Antibody Drugs Genor Biopharma Co. Ltd. Immunotherapy Cellular Biomedicine Group
Antibody Drugs Alphamab Co. Ltd Immunotherapy Eureka Therapeutics, Inc
Antibody Drugs Elpiscience Immunotherapy Vcanbio
Antibody Drugs Livzon International Limited Molecular Diagnostics Eppendorf
Antibody Drugs Lunan Pharmaceutical Group Molecular Diagnostics ACON Laboratories
Antibody Drugs Transcenta Molecular Diagnostics Genetron Health
Antibody Drugs Mabtech Limited Molecular Diagnostics Leadmanbio
Antibody Drugs GenScript Biotech Corporation Molecular Diagnostics DIAN DIAGNOSTICS GROUP CO LTD
Antibody Drugs Qilu Pharmaceutical Molecular Diagnostics Berryoncology
Antibody Drugs Johnson&Johnson Molecular Diagnostics Guangzhou KingMed Diagnostics Group Co., Ltd.
Antibody Drugs Humanwell Healthcare Molecular Diagnostics Sansure Biotech Inc.
Antibody Drugs RemeGen Molecular Diagnostics BGI
Antibody Drugs ChemPartner Molecular Diagnostics Getein Biotech, Inc.
Antibody Drugs 3SBIO INC. Molecular Diagnostics Singlera Genomics
Antibody Drugs Luye Pharma Group Molecular Diagnostics Luminex Corporation
Antibody Drugs EpimAb Biotherapeutics Molecular Diagnostics Roche diagnostics (shanghai) limited
Antibody Drugs Henlius Molecular Diagnostics Geneseeq Technology Inc.
Antibody Drugs JMT-BIO Molecular Diagnostics PerkinElmer
Antibody Drugs Shanghai Junshi Biosciences Co., Ltd. Molecular Diagnostics Hitachi
Antibody Drugs Etana Biotechnologies Hong Kong Limited Molecular Diagnostics Amoy Diagnostics
Antibody Drugs Roche Molecular Diagnostics Shanghai Kehua Bio-Engineering Co., Ltd.
Antibody Drugs Shanghai Miracogen Inc. Molecular Diagnostics 3dmedcare
Antibody Drugs NewBio Therapeutics, Inc. Molecular Diagnostics Liferiver Bio–Tech
Antibody Drugs Wuxi AppTec Molecular Diagnostics HaploX
Antibody Drugs Klus Pharma Inc. Molecular Diagnostics Shenzhen New Industries Biomedical Engineering Co., Ltd.
Antibody Drugs Suzhou Yabao Pharmaceutical R&D Co., Ltd. Molecular Diagnostics Wuhan YZY Medical Science&Technology Co.,Ltd
Antibody Drugs Tasly Group Molecular Diagnostics simceredx
Antibody Drugs Simcere Pharmaceutical Group Molecular Diagnostics Abbottmama
Antibody Drugs Innovent Molecular Diagnostics Autobio
Antibody Drugs YST Molecular Diagnostics Vcanbio
Antibody Drugs WuXi Biologics Investment Northern Light Venture Capital
Antibody Drugs Yichang Humanwell Pharmaceutical Co., Ltd Investment DeCheng Capital
Antibody Drugs Zai Lab Investment GTJA INVESTMENT GROUP
Antibody Drugs HISUN Investment GUOTAI JUNAN Securities
Antibody Drugs Zhejiang Huahai Pharmaceutical Co., Ltd. Investment China SDIC GaoXin Industrial Investment Corp., Ltd
Antibody Drugs Teruisi Investment China Resources (Holdings) Co., Ltd.
Antibody Drugs CTTQ Investment Jemincare
Antibody Drugs Akeso Biopharma Investment Legend Capital
Immunotherapy IQVIA Investment Warburg Pincus
Immunotherapy PersonGene Investment PING AN Ventures
Immunotherapy BoyaLife Investment PWC
Immunotherapy Fosun Kite Biotechnology Co., Ltd Investment SBCVC
Immunotherapy Fosun Pharma Investment Oriza Holdings

Conference Agenda of EBC 2020

Registration at EBC

Online registration:


3 Days Until RESI SF Partnering Launches!

5 Dec

By Bryanna Allison, Business Development Manager, LSN

Mark your calendar for Monday, December 9th. The partnering portal for RESI San Francisco will launch around 11am EST! First things first, are you registered for the conference? You will only have access to the partnering portal after you have registered. If you haven’t, please don’t wait!  It’s an advantage to be in partnering at launch in order to get the first touch out to investors.

The RESI Conference was designed as a partnering conference to ensure every one of your meetings is worthwhile, based on a strong fit between company and investor.  RESI Partnering provides fully tagged profiles of all the investors attending, based on interview conducted by LSN’s Investor Research team.  Our RESI Premier Partnering attendees can also see in depth profiles on investor technology interests and get direct contact with investors.  Would you like to meet with these investors, and more?  Sign up for RESI now.


As of Dec. 3rd, 2019



Last Call for RESI SF Innovation Challenge Applications!

5 Dec

By Karen Deyo, Senior Investor Research Analyst, LSN

The deadline for applying to the RESI SF Innovation Challenge is tomorrow, Friday, Dec. 6th, and this is the last call for companies to submit their applications for consideration. The Innovation Challenge is a unique competition, where companies are selected using criteria such as innovativeness, stage of development, market size and opportunity and competitive landscape. The top companies, identified for their ‘investability,’ present posters in the exhibit hall on the day of the conference, competing for ‘investments’ of ‘RESI Cash’ from attendees to win prizes.

Participation in the Innovation Challenge can benefit finalists in many ways, including the increased exposure gained by the feature in the LSN Newsletter, the printed RESI Program Guide, as well as onsite signage at RESI. In addition, companies that actively seek ‘investments’ from attendees find that this can lead to many productive ad hoc meetings, furthering their fundraising campaigns in sometimes unexpected ways.

Click here to apply to the Innovation Challenge – good luck!


Artificial Intelligence is the Future of Healthcare

5 Dec

By Lucy Parkinson, VP of Investor Research, LSN

At LSN we speak to investors day in, day out, about what technologies they are seeking for their future portfolios. Many are now looking for artificial intelligence (AI) solutions across all of the sectors that LSN covers – drugs, devices, diagnostics and digital health. Investors are interested in the power of AI: from drug discovery tools to data analytics, from genomics to clinical decision support, and also including image analysis and patient monitoring, to name a few.

It’s clear that there is an emerging interest in bringing these fields together. LSN has already used RESI to dip our toes in the water of AI, with regular panels on AI in Healthcare; at RESI Taipei, Professor Jack Li delivered a presentation on the future AI landscape of healthcare, which highlighted the role AI can play in lowering the costs of future care delivery. We’ve found these topics have resonated with both investors and entrepreneurs in early stage life sciences. There are many avenues for adding AI as an extra dimension to new technologies, such as using AI to analyze data from new drugs or devices.

RESI San Francisco will include two investor panels specifically devoted to artificial intelligence: the broad AI in Healthcare panel, and a more focused panel on AI in Pathology and Imaging, a key sector for the advancement of healthcare AI.  AI is also a key topic in other panels such as Oncology Innovation and Investing in Life Science Tools.  With so much innovation happening in this space, RESI hopes to help investors and entrepreneurs who are focused on healthcare AI connect with each other.

LSN is planning further dedicated content in this space; look out for the launch of 4D Meets AI soon.

Global Family Office BioForum to Sponsor RESI’s 2020 Events Worldwide

5 Dec

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

We are delighted to announce that the Global Family Office Bioforum (GFOB) will be RESI’s title sponsor for 2020.

The Global Family Office BioForum (GFOB) is the leading alliance of international Family Offices focused on healthcare/life science which meets quarterly in 18 cities in the US, Europe and Asia.  GFOB also has a joint partnership with Life Science Nation and the RESI conference Series. These initiatives aim to assist the earliest stage life sciences companies by sourcing seed capital and management talent.


%d bloggers like this: